Legal & General Group Plc Raises Holdings in Regenxbio Inc (RGNX)

Legal & General Group Plc grew its holdings in shares of Regenxbio Inc (NASDAQ:RGNX) by 919.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 53,386 shares of the biotechnology company’s stock after purchasing an additional 48,150 shares during the quarter. Legal & General Group Plc owned about 0.17% of Regenxbio worth $3,831,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of RGNX. Victory Capital Management Inc. boosted its position in Regenxbio by 12.3% during the first quarter. Victory Capital Management Inc. now owns 67,159 shares of the biotechnology company’s stock worth $2,005,000 after purchasing an additional 7,330 shares during the period. Prudential Financial Inc. lifted its holdings in shares of Regenxbio by 45.2% in the first quarter. Prudential Financial Inc. now owns 33,910 shares of the biotechnology company’s stock worth $1,012,000 after buying an additional 10,560 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Regenxbio by 7.7% in the first quarter. Swiss National Bank now owns 45,900 shares of the biotechnology company’s stock worth $1,370,000 after buying an additional 3,300 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Regenxbio by 5.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 135,094 shares of the biotechnology company’s stock worth $4,033,000 after buying an additional 6,907 shares in the last quarter. Finally, Citigroup Inc. lifted its holdings in shares of Regenxbio by 21.0% in the first quarter. Citigroup Inc. now owns 97,113 shares of the biotechnology company’s stock worth $2,899,000 after buying an additional 16,846 shares in the last quarter. Hedge funds and other institutional investors own 80.81% of the company’s stock.

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley increased their price target on shares of Regenxbio from $37.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday, July 13th. Barclays increased their price target on shares of Regenxbio from $48.00 to $83.00 and gave the stock an “overweight” rating in a report on Monday, August 13th. Raymond James increased their price target on shares of Regenxbio from $76.00 to $96.00 and gave the stock an “outperform” rating in a report on Friday, September 7th. BidaskClub downgraded shares of Regenxbio from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 25th. Finally, Chardan Capital increased their price target on shares of Regenxbio from $90.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, July 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $77.64.

Shares of Regenxbio stock opened at $71.75 on Tuesday. Regenxbio Inc has a 12-month low of $23.25 and a 12-month high of $85.10. The stock has a market capitalization of $2.24 billion, a PE ratio of -29.22, a PEG ratio of 13.91 and a beta of -1.18.

Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.93). The firm had revenue of $40.03 million during the quarter, compared to analysts’ expectations of $100.00 million. Regenxbio had a return on equity of 28.70% and a net margin of 44.44%. research analysts predict that Regenxbio Inc will post 1.64 EPS for the current year.

In related news, SVP Patrick J. Christmas sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 20th. The shares were sold at an average price of $65.96, for a total value of $329,800.00. Following the sale, the senior vice president now directly owns 22,669 shares of the company’s stock, valued at $1,495,247.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Vittal Vasista sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $75.54, for a total transaction of $566,550.00. Following the completion of the sale, the chief financial officer now directly owns 134,655 shares in the company, valued at $10,171,838.70. The disclosure for this sale can be found here. Insiders sold 42,520 shares of company stock worth $3,010,214 over the last ninety days. 16.90% of the stock is currently owned by insiders.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Recommended Story: Growth Stocks, What They Are, What They Are Not

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply